First Light Asset Management LLC Has $66.25 Million Holdings in Guardant Health, Inc. $GH

First Light Asset Management LLC increased its position in shares of Guardant Health, Inc. (NASDAQ:GH) by 57.5% during the second quarter, HoldingsChannel.com reports. The fund owned 441,586 shares of the company’s stock after acquiring an additional 161,287 shares during the period. Guardant Health makes up approximately 4.0% of First Light Asset Management LLC’s holdings, making the stock its 8th largest holding. First Light Asset Management LLC’s holdings in Guardant Health were worth $66,251,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of GH. California State Teachers Retirement System raised its position in shares of Guardant Health by 16,079.2% in the second quarter. California State Teachers Retirement System now owns 21,129,925 shares of the company’s stock worth $3,170,123,000 after buying an additional 20,999,326 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Guardant Health by 33.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,636,078 shares of the company’s stock valued at $575,670,000 after acquiring an additional 1,414,441 shares in the last quarter. Franklin Resources Inc. boosted its position in shares of Guardant Health by 14.9% during the 4th quarter. Franklin Resources Inc. now owns 3,361,547 shares of the company’s stock valued at $343,348,000 after acquiring an additional 435,232 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Guardant Health by 9.4% during the fourth quarter. Geode Capital Management LLC now owns 3,213,657 shares of the company’s stock worth $328,297,000 after purchasing an additional 277,001 shares in the last quarter. Finally, Fuller & Thaler Asset Management Inc. increased its position in shares of Guardant Health by 3.0% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 2,441,730 shares of the company’s stock worth $249,398,000 after purchasing an additional 72,162 shares during the last quarter. 92.60% of the stock is owned by institutional investors.

Insider Activity

In other news, insider Chris Freeman sold 63,605 shares of the firm’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $169.58, for a total value of $10,786,135.90. Following the completion of the sale, the insider directly owned 65,374 shares of the company’s stock, valued at approximately $11,086,122.92. This trade represents a 49.31% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Musa Tariq sold 1,951 shares of the business’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $131.16, for a total transaction of $255,893.16. Following the transaction, the director owned 11,048 shares in the company, valued at $1,449,055.68. This represents a 15.01% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 427,024 shares of company stock valued at $67,113,285. 5.60% of the stock is owned by insiders.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Royal Bank Of Canada lifted their target price on shares of Guardant Health from $185.00 to $200.00 and gave the company an “outperform” rating in a research report on Friday, July 31st. TD Cowen reiterated a “buy” rating on shares of Guardant Health in a research report on Tuesday, August 25th. The Goldman Sachs Group restated a “buy” rating and set a $210.00 price target on shares of Guardant Health in a research report on Friday, July 31st. Guggenheim raised their price objective on Guardant Health from $160.00 to $190.00 and gave the company a “buy” rating in a report on Thursday, July 16th. Finally, Sanford C. Bernstein upped their target price on Guardant Health from $175.00 to $200.00 and gave the stock an “outperform” rating in a research note on Thursday, July 2nd. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $187.71.

Guardant Health Stock Up 1.1%

Shares of GH opened at $162.78 on Thursday. The stock has a market capitalization of $21.85 billion, a P/E ratio of -46.64 and a beta of 1.57. Guardant Health, Inc. has a twelve month low of $53.40 and a twelve month high of $176.58. The firm has a fifty day simple moving average of $160.11 and a two-hundred day simple moving average of $124.02.

Guardant Health (NASDAQ:GH) last posted its earnings results on Thursday, July 30th. The company reported ($0.42) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.34. The firm had revenue of $334.98 million for the quarter, compared to analysts’ expectations of $314.23 million. During the same quarter in the prior year, the company posted ($0.44) earnings per share. The business’s revenue for the quarter was up 44.3% on a year-over-year basis. Sell-side analysts expect that Guardant Health, Inc. will post -2.98 EPS for the current fiscal year.

Guardant Health Profile

Guardant Health, Inc (NASDAQ:GH) is a precision oncology company that develops blood-based diagnostic tests designed to help detect cancer, guide treatment decisions and monitor patients over time. Its liquid biopsy technologies analyze tumor-related signals in blood, reducing the need for tissue biopsies in certain clinical and research settings.

The company’s products include Guardant360 tests, which profile advanced cancers and can help identify potentially actionable genomic alterations; Guardant Reveal, which is used to assess residual disease and recurrence risk; and Guardant Shield, a blood-based screening test for colorectal cancer.